GDC-6036 in combination w/other anti-cancer therapies in untreated metastatic NSCLC w/KRAS G12C mut

A Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation

For More Information:

https://clinicaltrials.gov/study/NCT04449874?term=NSCLC%20G12C%20mutation%20GDC-6036%20&rank=1